Skip to content

Disease management of depression and anxiety in primary care patients with diabetes, asthma and/or COPD.

Disease management of depression and anxiety (DiMaCoDeA) in primary care patients with diabetes mellitus, asthma and/or COPD.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25921
Enrollment
320
Registered
2010-11-18
Start date
2011-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression, anxiety, diabetes, asthma, chronic obstructive pulmonary disease (COPD) depressie, angst, diabetes, astma, COPD

Interventions

The current study is a randomized control trial, with an intervention of one year and an additional one year follow up. Randomization will be at patient level. All eligible primary care patients with
2) Care as usual. Intervention group: Disease management for depression and anxiety. The patients in the disease management arm will receive stepped care program for depression and anxiety. After ea
Step 2: Coping with depression / anxiety course. The course takes approximately 10 weeks to complete and is given individually. Improved (PHQ-9 monitoring. Not improved --> step 3
Step 3: Extension of the course with an option for additional drug treatment. Monitoring phase: Each three months the patients are monitored using the PHQ

Sponsors

Tilburg University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Having diabetes, asthma and/or COPD in primary care; 2. Depressive symptoms or anxiety symptoms; 3. 18 years or older.

Exclusion criteria

Exclusion criteria: 1. Current treatment for depression and/or anxiety; 2. Major psychiatric problems (e.g. schizophrenia, suicidality, bipolar disorder); 3. Not being able to read or speak Dutch sufficiently; 4. Being younger than 18 years old.

Design outcomes

Primary

MeasureTime frame
1. Depressive symptoms (PHQ-9); 2. Anxiety symptoms (GAD-7).

Secondary

MeasureTime frame
1. Quality of life (SF-12, ADDQoL, CCQ); 2. Disease specific distress (PAID); 3. Health care costs (TiC-P, EuroQoL); 4. Self-management and life style behaviours (SDSCA, SQUASH, medication adherence); 5. Satisfaction (PEQD).

Contacts

Public ContactC.H. Stoop

Provincialeweg 44

c.stoop@pozob.nl+31 (0)40 2306945

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)